Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Int J Mol Sci. 2023 Jul 25;24(15):11903. doi: 10.3390/ijms241511903.
To achieve the scheme of "magic bullets" in antitumor therapy, antibody-drug conjugates (ADCs) were developed. ADCs consist of antibodies targeting tumor-specific antigens, chemical linkers, and cytotoxic payloads that powerfully kill cancer cells. With the approval of ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (T-DXd), the therapeutic potentials of ADCs in breast cancer have come into the spotlight. Nearly 30 ADCs for breast cancer are under exploration to move targeted therapy forward. In this review, we summarize the presenting and emerging agents and targets of ADCs. The ADC structure and development history are also concluded. Moreover, the challenges faced and prospected future directions in this field are reviewed, which give insights into novel treatments with ADCs for breast cancer.
为了实现抗肿瘤治疗中的“神奇子弹”方案，开发了抗体药物偶联物（ADCs）。ADC 由靶向肿瘤特异性抗原的抗体、化学连接子和有效杀死癌细胞的细胞毒性有效载荷组成。随着 ado-trastuzumab emtansine（T-DM1）和 fam-trastuzumab deruxtecan（T-DXd）的批准，ADC 在乳腺癌中的治疗潜力引起了关注。目前有近 30 种用于乳腺癌的 ADC 正在探索中，以推进靶向治疗。在这篇综述中，我们总结了 ADC 的现有和新兴药物和靶点。还总结了 ADC 的结构和发展历史。此外，还回顾了该领域面临的挑战和未来展望方向，为乳腺癌的 ADC 治疗提供了新的思路。
